NovaBridge Biosciences R&D Spending Growth & History (NBP)
NovaBridge Biosciences's r&d spending was $62.9M for fiscal 2025.
View full NovaBridge Biosciences company overviewNovaBridge Biosciences annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $62.9M | $41.1M | +188.95% |
| 2024 | 2024-12-31 | $21.8M | $322,000 | +1.50% |
| 2023 | 2023-12-31 | $21.4M | −$1.1M | −4.87% |
| 2022 | 2022-12-31 | $22.5M | −$167.8M | −88.15% |
| 2021 | 2021-12-31 | $190.3M | $39.4M | +26.13% |
| 2020 | 2020-12-31 | $150.9M | $30.2M | +25.01% |
| 2019 | 2019-12-31 | $120.7M | — | — |
NovaBridge Biosciences quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | $55.7M | $49.6M | +823.02% |
| Q3 2025 | 2025-09-30 | $3.2M | −$1.3M | −29.03% |
| Q2 2025 | 2025-06-30 | $3.3M | — | — |
| Q1 2025 | 2025-03-31 | $777,000 | — | — |
| Q4 2024 | 2024-12-31 | $6.0M | — | — |
| Q3 2024 | 2024-09-30 | $4.5M | — | — |
NovaBridge Biosciences r&d spending trends
Over the last five fiscal years, NovaBridge Biosciences's r&d spending decreased from $150.9M to $62.9M, a change of −$88.0M. The latest reported quarter, Q4 2025, shows $55.7M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NovaBridge Biosciences source filings ↗